Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Some of the greatest advances in the treatment of solid malignancies have resulted from the combination of chemotherapy and radiotherapy treatments. This article comprehensively reviews the current clinical evidence for oxaliplatin-based chemo-radiotherapy that may improve local control and survival. In order to understand how clinical studies should be designed, the pre-clinical evidence for the use of oxaliplatin chemotherapy as a radiosensitising agent is appraised. Particular focus is placed on oxaliplatin's biological mechanisms of action, including cell cycle effects, the formation of DNA adducts and interstrand cross-links and the role of DNA repair proteins. At a clinical level, there is currently no evidence to suggest that oxaliplatin provides an additional benefit to concurrent chemo-radiation regimes that utilise fluoropyrimidines; we evaluate the reasons for this observation, the limitations of clinical trial design and the opportunities that currently exist to design clinical trials which are underpinned by an understanding of the basic biology.

Original publication

DOI

10.1016/j.critrevonc.2011.12.007

Type

Journal article

Journal

Crit Rev Oncol Hematol

Publication Date

09/2012

Volume

83

Pages

353 - 387

Keywords

Animals, Antineoplastic Agents, Biomarkers, Tumor, Clinical Trials as Topic, Combined Modality Therapy, Digestive System Neoplasms, Humans, Organoplatinum Compounds, Oxaliplatin, Radiation Tolerance, Radiation-Sensitizing Agents, Translational Medical Research